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Abstract
Ion channels are progressively emerging as a novel class of membrane proteins expressed in several types of human
cancers and regulating the different aspects of cancer cell behavior. The metabolism of cancer cells, usually
composed by a variable proportion of respiration, glycolysis, and glutaminolysis, leads to the excessive production
of acidic metabolic products. The presence of these acidic metabolites inside the cells results in intracellular
acidosis, and hinders survival and proliferation. For this reason, tumor cells activate mechanisms of pH control that
produce a constitutive increase in intracellular pH (pHi) that is more acidic than the extracellular pH (pHe). This
condition forms a perfect microenvironment for metastatic progression and may be permissive for some of the
acquired characteristics of tumors. Recent analyses have revealed complex interconnections between oncogenic
activation, ion channels, hypoxia signaling and metabolic pathways that are dysregulated in cancer. Here, we
summarize the molecular mechanisms of the Warburg effect and hypoxia and their association. Moreover, we
discuss the recent findings concerning the involvement of ion channels in various aspects of the Warburg effect and
hypoxia, focusing on the role of Na+ and K+ channels in hypoxic and metabolic reprogramming in cancer.
Keywords: ion channels, Warburg effect, cancer
Introduction
Metabolic alterations represent one of the emerg-ing hallmarks of cancer.1 During cancerogenesis, neo-
plastic cells occupy increasingly ‘‘poorer’’ microenvironments
and to maintain their viability and build new biomass, cancer
cells rely strongly on their ability to utilize low-level nutri-
ents present in the microenvironment and/or supplied by a
progressively deficient vascularization.1,2 Thus, it is not sur-
prising that cancer cells reprogram their metabolism during
tumor progression. Such altered metabolism not only permits
cancer cells to survive under adverse conditions, such as hyp-
oxia, but also enables their proliferation, growth, invasiveness,
and metastasis.2 Such reprogramming can occur as both direct
and indirect consequences of oncogenic alterations, including
mutations. Conversely, the alterations in intracellular and
extracellular metabolites that accompany cancer-associated
metabolic reprogramming can have profound effects on gene
expression, cellular differentiation, and on the tumor micro-
environment itself, thus creating a vicious circle.2
Several metabolic changes characterize cancer cells: de-
regulated glucose uptake and utilization, increased gluco-
neogenesis and increased glutaminolytic activity, reduced
fatty acid oxidation, increased de novo fatty acid synthesis,
increased glycerol turnover, modified amino acid metabo-
lism, and increased pentose phosphate pathway (PPP) ac-
tivity.2,3 One of the metabolic alterations most commonly
displayed by many, if not all, cancer types, is an increased
rate of intracellular glucose import and a higher rate of gly-
colysis associated with reduced pyruvate oxidation and in-
creased lactic acid production, the so-called Warburg effect.4
In turn, the increased lactate production contributes to ex-
tracellular acidification, another characteristic of malignant
transformation. The enhanced glycolysis in cancer cells was
initially traced back to insufficient cellular respiration as
causative of cancer (Warburg’s own hypothesis). Subse-
quently, however, it was shown that theWarburg effect is not
a primary cause of malignancy,5 but a downstream condition.
Nevertheless, such an metabolic alteration has been exploited
clinically for diagnostic and prognostic purposes. For ex-
ample, in positron emission tomography, imaging of the
uptake of a radioactive fluorine-labeled glucose analog, 18F-
fluorodeoxyglucose, is used for cancer diagnosis and staging,
as well as for monitoring response to treatment.6
The cause(s) of the upregulation of glycolysis in cancer has
not been conclusively elucidated, and several hypotheses
have been proposed, including microenvironmental adapta-
tion,7 conferral of biosynthetic advantages8 and the presence
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of hypoxic conditions inside malignant and premalignant
lesions.9 Indeed, hypoxia is an intrinsic characteristic of
growing tumors, to which cancer cells adapt by increasing
angiogenesis and which, in turn, may cause genetic insta-
bility and hence accumulation of further malignancy-driving
mutations.10
A novel hallmark of cancer cells is the dysregulation of
their ionic activity, involving ion channels and transporters
(ICTs), transmembrane proteins that are becoming important
players in cancer.11–13 Indeed, the expression and activity of
different ion channel types mark and regulate specific stages
of cancer progression and their contribution to the neoplastic
phenotype ranges from control of cell proliferation and ap-
optosis, to regulation of invasiveness.11–13 While substantial
work has been done on a range of tumor cell lines, recent
evidence has shown that blocking channel activity can impair
tumor growth and metastasis also in vivo.14 Consequently,
altered ICT expression can be exploited for diagnostic pur-
poses and/or for targeting traceable or cytotoxic compounds
to specific neoplastic tissues.15
The aim of the present review is to summarize current
knowledge about the possible role of ICTs in the Warburg
effect. We first describe (i) the involvement of hypoxia in the
Warburg effect and (ii) the main pathophysiological char-
acteristics of ICTs in cancer, focusing on Na+ and K+ chan-
nels. Finally, we evaluate a possible converging hypothesis
involving the Warburg effect, hypoxia, and Na+ and K+
channels, and we discuss the emerging strategies to target
ICTs in tumor treatment.
The Warburg Effect
Overview of the general mechanisms
of increased aerobic glycolysis in cancer
Following the observation of a decrease in oxygen uptake
caused by glucose in cancer cells, the so-called Crabtree effect,
Otto Warburg showed that malignant transformation is asso-
ciatedwith an increased rate of cellular glucose import and that
a higher glycolysis rate is associated with reduced pyruvate
oxidation and increased lactic acid production.4,16,17 In normal
conditions, glycolysis occurs when the oxygen concentration is
low, but in cancer it also occurs in the presence of adequate
oxygenation. Hence, cancer cells are characterized by the
so-called aerobic glycolysis,4,17,18 this metabolic shift being
maintained throughout tumor progression,
Working under the assumption that the major use of glu-
cose in cancer cells was to generate adenosine triphosphate
(ATP), Warburg and others misinterpreted this phenomenon,
attributing it to the ‘‘irreversible injuring of respiration.’’17
In normal cells, influx of glucose into normal cells is not
driven by the immediate bioenergetic needs of a cell but is
strictly rationed as a result of extracellular stimuli. Further-
more, in case of growth factor deprivation, cell survival can be
restored by upregulation of the glucose transporter 1 (GLUT-1)
on the plasma membrane as well as hexokinase (HK).19 On the
contrary, cancer cells accumulate oncogenic alterations that
make their metabolic requirements to be substantially inde-
pendent of external stimuli.4 Such changes involve phosphoi-
nositide 3 kinase (PI3K), its negative regulators phosphatase
and tensin homolog (PTEN) and INPP4B, and activating mu-
tations and gene amplifications in a variety of upstream re-
ceptor tyrosine kinases.1,20 PI3K/Akt signaling acts as a master
regulator of glucose uptake, promoting both the mRNA ex-
pression of GLUT-1 and translocation of the protein from en-
domembranes to cell surface.21,22 In addition, Akt potentiates
the activities of HK and phosphofructokinase (PFK), which
catalyze the key irreversible step of glycolysis.23,24 Overall,
multiple growth factor signaling pathways aberrantly activated
in cancer can facilitate the utilization of glucose by cancer
cells7 (Table 1).When a tumor cell is ‘‘quiescent’’, similar to
normal cells, glucose is preferentially utilized for genera-
tion of acetyl-CoA, which is then oxidized in the tricar-
boxylic (TCA) cycle in mitochondria. In turn, this produces
NADH and FADH2 and contributes to the generation of the
electrochemical gradient that fuels ATP production. Still,
the ‘‘carbon economy’’ of a proliferating normal cell dif-
fers dramatically from that of a quiescent cancer cell.8
The major use of reduced carbon in proliferating cells is
for the biosynthesis of a diverse array of biomolecules. To
accomplish this, nutrients must be transformed into diverse
pools of structural intermediates. In these reactions, the
donor of reducing equivalents is NADPH. Hence, a prolif-
erating cell must allocate a portion of its carbon substrates to
be used in NADPH production instead of NADH to support
mitochondrial electron transport. The reprogramming of
carbon metabolism by proliferating cancer cells provides
part of the explanation for Warburg’s original observations
concerning tumor metabolism. Rather than being an adap-
tation to a defect in respiration, the Warburg effect is a
regulated metabolic state and may, in fact, be beneficial
during a time of increased biosynthetic demand.4
It was recently shown that by converting excess pyruvate to
lactate, proliferating cells prevent accumulation of cytosolic
NADH and reduce ATP production. In turn, this promotes
continued cytosolic glucose metabolism free from feedback
repression by excess ATP generated in mitochondria.3 It is
worth recalling that a number of glycolytic intermediates can be
diverted into branching pathways, generating diverse biosyn-
thetic precursors. First, the PPP, in which glucose-6-phosphate
becomes partially oxidized to generate NADPH and ribose-5-
phosphate, a structural component of nucleotides. Utilization of
PPP is frequently elevated in tumorigenesis, and both onco-
genes and tumor suppressors regulate PPP activity, for example,
Ras activates it31 while p53 is inhibitory.32 Second, fructose-6-
phosphate, which follows glucose-6-phosphate in the glycolytic
pathway, can also leave glycolysis and become utilized as a
substrate for hexosamine biosynthesis. The hexosamine path-
way provides substrates for cellular glycosylation reactions (as
well as heparan sulfate and hyaluronic acid biosynthesis), po-
tentiates receptor-mediated signaling, and regulates the stability
of select proteins, including the transcription factor, c-myc.33–35
Third, dihydroxyacetone phosphate, is utilized in the biosyn-
thesis of diverse phospholipids, amajor structural component of
cellular membranes. Fourth, 3-phosphoglycerate is used as a
precursor for biosynthesis of serine and glycine, and as a means
to generate methyl donor groups and NADPH.36,37 Serine has a
unique metabolic role as a major substrate for the so-called one-
carbon or folate cycle, which in turn contributes to the bio-
synthesis of purines, thymidine, as well as in the production of
S-adenosylmethionine, a principal substrate for cellular meth-
ylation reactions.38 In addition, stepwise oxidation of one-
carbon tetrahydrofolate species was recently shown to produce
up to 50% of all cellular NADPH.39 Thus, one-carbon pathway
metabolites contribute to a number of cellular biosynthetic and
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regulatory processes. Finally, methylene tetrahydrofolate de-
hydrogenase 2, a component of the mitochondrial arm of the
one-carbon pathway, was found to be among the top three most
frequently overexpressed metabolic enzymes in cancer, sug-
gesting that alterations in this pathway may be universally se-
lected for tumorigenesis.40
In conclusion, glycolytic intermediates leave glycolysis to
take part in diverse biosynthetic reactions. Consequently, the
rate-limiting enzymes within branching pathways of glycol-
ysis are frequently upregulated in tumors. Thus, proliferating
cells have evolved a novel mechanism to regulate the last step
of glycolysis, balancing its biosynthetic outputs with pro-
viding pyruvate that supports the TCA cycle. This step is
regulated by pyruvate kinase (PK), an enzyme that converts
phosphoenolpyruvate to, the final product of glycolysis, py-
ruvate. With the exception of liver and kidney, which express
tissue-specific PK isoforms (PKL and PKR, respectively),
most tissues express the PKM (muscle) form of PK. The latter
exists as two splice variants.41 While PKM1 is more efficient
at producing pyruvate, the majority of proliferating cells and
essentially all cancer cells express primarily the PKM2 var-
iant.42 Importantly, unlike PKM1, the activity of PKM2 is
highly regulated, inhibited by tyrosine and activated by serine
phosphorylation.43–45 In such a manner, growth factor sig-
naling inhibits PKM2, leading to accumulation of glycolytic
intermediates until the growing cell’s need for a catabolizable
pool of free serine is saturated. The emerging evidence favors
the hypothesis that glycolysis is utilized by proliferating cells
as a versatile production line that generates metabolic inter-
mediates for numerous biosynthetic processes. Any excess,
nonutilized glycolytic flux is preferentially converted to
lactate to help preserve a sufficient pool of NAD+ to sustain
glycolysis and avoid flooding the mitochondria with NADH
that would suppress the TCA cycle.46
A variety of oncogenes have been shown to contribute to
the metabolic adaptations of proliferating cells, as outlined
above. For instance, c-myc coordinates increase in the ex-
pression of (i) pyruvate dehydrogenase kinase isozyme 1
(PDK1), (ii) lactate dehydrogenase A (LDHA), an enzyme
that catalyzes the reductive conversion of pyruvate to lactate,
and (iii) monocarboxylate transporter (MCT1), facilitating
the efflux of lactate into the extracellular space.47 In addition
to c-myc, b-catenin/T cell factor signaling has also been
shown to upregulate MCT1 and PDK1 transcription.48 Fi-
nally, hypoxia or different oncogenic stress can also trigger
coordinated transcriptional upregulation of LDHA and
PDK1.49,50 Even with these adaptations, however, prolifer-
ating cells often accumulate electron transport flux that ex-
ceeds the capacity of the ATP synthase, resulting in the
formation of excess reactive oxygen species (ROS). In fact,
the damaging consequences of such overproduction of ROS
may underlie the phenomenon of oncogene-induced cellular
senescence.
Overview of molecular mechanism of hypoxia
and of hypoxia-induced metabolic
reprogramming in cancer cells
Hypoxia, reduction in the normal level of tissue oxygen
tension (pO2) to less than 15mmHg, is a common charac-
teristic of locally advanced solid tumors. This occurs as a
consequence of the uncontrolled proliferation of cancer cells
that quickly consume nutrients and oxygen supply from the
vasculature. Cancer cells are able to sense changes in oxygen
tension and to develop adaptive changes, enabling survival
and even prolonging proliferation. These adaptive processes
contribute to the development of the malignant phenotype
and limit therapeutic responses.51
The adaptation to reduced O2 tension is characterized by
different hypoxia-stimulated biological mechanisms driven
by the hypoxia-inducible factor 1 (HIF-1) (Table 2). HIF-1,
identified in 1992 by Semenza andWang, is a mediator of the
primary transcriptional adaption to hypoxic stress in cancer,
upregulating the expression of erythropoietin.52 HIF-1 is a
heterodimer comprising two subunits, the cytoplasmic hyp-
oxic response factor HIF-1a and the aryl hydrocarbon re-
ceptor nuclear translocator (ARNT), also known as HIF-1b.53
Whereas HIF-1b is constitutively expressed independently of
pO2 tension, HIF-1a is responsive to O2 levels. Under nor-
moxic conditions (21% O2), HIF-1a is hydroxylated by the
prolyl hydroxylase domain protein (PHD), which promotes
binding to the von Hippel–Lindau (VHL) protein.54 This
interaction leads to ubiquitylation and rapid degradation of
HIF-1a. Since the activity of PHD requires O2, it cannot
modify HIF-1a under hypoxic conditions. In cells exposed to
reduced O2 levels, stable HIF-1a subunits translocate to the
nucleus where they heterodimerize with HIF-1b subunits,
leading to an active HIF-1 protein that binds to specific
hypoxia-response elements (HREs) and regulates the tran-
scriptional activity of numerous target genes.55
Since its discovery, HIF-1 has been shown to be associated
with several biological pathways such as the induction of
neovascularization.56 HIF-1 activates the transcription of
vascular endothelial growth factor (VEGF) in cancer cells
and of its receptor VEGR1 in endothelial cells. HIF-1 also
induces expression of growth factors that stimulate prolifer-
ation and promote proteolysis and factors that stimulate
cellular migration.51,57 Moreover, the constitutive expression
of HIF-1, resulting from genetic alterations, could lead to
tumor invasion.58 On the contrary, HIF-1 can also regulate
proapoptotic genes, causing autophagy or cell death. In the
latter, HIF has been linked to p53, although both interactive
and competitive mechanisms have been described.59 Further
studies relating necrotic regions of tumors to blood vessel
disposition suggested that necrosis was, at least in part, driven
by hypoxia. This dual effect of hypoxia in solid tumors has
been described as a direct consequence of the oxygen gra-
dient. Besides PHD-mediated regulation, HIF-1 action is
inhibited by another oxygen sensor, the asparaginyl hy-
droxylase factor inhibiting HIF-1 (FIH).60 The catalytic
profiles of these two hydroxylases are different in the oxygen
sensing pathway.61 FIH hydroxylates an asparagine residue
(N803) in the carboxy-terminal transactivation domain of
HIF-1a. In the peripheral tumor area with mild hypoxia, al-
though PHD activity is arrested and HIF-1a could hetero-
dimerize with HIF-1b, FIH is still active for its higher affinity
to O2 than PHD and, in these conditions, the inhibition of
HIF-1a is still maintained in the carboxy-terminal transacti-
vation domain by FIH. In highly hypoxic tumor regions, the
catalytic activities of both hydroxylases are inhibited and
HIF-1a attains full transcriptional activity, leading to apo-
ptotic and necrotic processes.61
There are several other factors, especially various onco-
genic pathways that can increase HIF-1a protein levels,
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independent of hypoxia.75 For example, HRAS-V12 leads to
the accumulation of HIF-1a in both normoxic and hypoxic
conditions.76 Increased HIF-1 targets are associated with
pathways of Ras-MAPK62 and PI3K-Akt.63–65 Direct acti-
vation of PI3K itself or the downstream kinase Akt, or loss of
the inhibitory PTEN tumor suppressor, leads to increased
HIF-1a levels and activity. It has also been demonstrated that
Akt increases HIF-1a translation by both mechanistic target
of rapamycin (mTOR)-dependent and mTOR-independent
mechanisms.75
Recently, attention has been focused onto the concept of
‘‘intermittent hypoxia.’’ In solid tumors, intermittent hyp-
oxia associated with irregular blood supply can cause the
switching of hypoxia and reoxygenation phases. Compared
with those induced by chronic hypoxia, this exerts different
effects on HIF-1 stabilization and HIF-1 target gene tran-
scription.77 In vitro and in vivo studies have shown that in-
termittent hypoxia affects both tumor and endothelial cells
and the interplay between them, resulting in rapidly growing
tumors and the development of new vascular networks. Ul-
timately, intermittent oxygen exposure has been also linked
to an accelerated tumor progression, metastasis, and resis-
tance to therapies.69
HIF-1 also has an important role in driving aerobic gly-
colysis to meet the biosynthetic demand and to prevent cells
from hypoxic stress damage.66 The mechanisms underlying
the hypoxia-induced metabolic reprogramming in cancer
cells are well documented. Low O2 levels increase the need
for glucose and upregulate GLUT-1 and GLUT-3 expression.
Simultaneously, lactate production is increased enhancing
the activity of glycolytic enzymes, including HK1, HK2,
PKM2, and LDHA.66 There is also a feedback mechanism
Table 2. Hypoxia Regulatory Factors and Their Role in Cancer
Hypoxia
regulatory
factors Function Role in cancer cell Signaling pathways
Regulation by Na+
and K+ channels
HIF-1 Transcription factor. Regulates the cellular and
homeostatic response to
hypoxia.52,53
Heterodimerization of HIF-
1a and HIF-1b
subunits.53–55
HIF-1a Alpha subunit of
transcription factor
hypoxia-inducible
factor-1.
Stabilized in cancer even
under normoxic
conditions.
Activates the transcription
of many genes,
including those involved
in cancer cell
proliferation (e.g., TGF-
a), angiogenesis (e.g.,
VEGF), erythropoiesis,
apoptosis (e.g., BNip3
and p53), stress-
response pathways, cell
adhesion, migration, and
pH regulation
(CAIX).51,56–59
Induces glucose
consumption and lactate
production, upregulating
glucose transporters,
glycolytic enzymes,
LDH-A, and MCT4, and
inhibiting PDH through
activation of PDK1.66–72
Oxygen sensors: the prolyl
hydroxylase domain
(PHD) proteins and the
asparaginyl hydroxylase
factor inhibiting HIF-1
(FIH).60,61
Phosphorylation by
MAPK.62
Oncogenic signaling
pathways involving SRC,
RAS, Akt, PI3K, and
mTOR, PTEN or p53
loss.61,63–65
Ligands of tyrosine kinase
receptors (e.g., EGFR and
HER2).
Interaction with
transcription factors such
as AP-1, ETS, and the
cyclic AMP-response
element-binding protein
(CREB).66–68
CAIX expression and
mutations in VHL.64
Kv10.1 expression
increases basal
expression levels of
HIF-1a and increases
response of cells to
mild hypoxia. This
leads to VEGF
secretion and
neovascularization.73
Kv11.1 (also named
hERG1) couples with
b1 integrin and
regulates a signaling
pathway that sustains
VEGF-A secretion,
angiogenesis, and
progression in
colorectal cancer. In
this pathway, Kv11.1
recruits and activates
PI3K and Akt. This in
turn increases HIF-
dependent
transcription of
VEGF-A and other
tumor progression
genes.74
ARNT (also
known as
HIF-1b)
Binds to ligand-bound
aryl hydrocarbon
receptor and aids in
the movement of
this complex to the
nucleus.
Cofactor for
transcriptional
regulation by hypoxia-
inducible factor 1.53
Constitutively expressed in
normoxic conditions.
AMP, adenosine monophosphate; AP-1, activator protein 1; ARNT, aryl hydrocarbon receptor nuclear translocator; BNip3, BCL2
interacting protein 3; CAIX, carbonic anhydrase-9; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor
receptor 2; HIF-1, hypoxia-inducible factor 1; Kv, voltage-gated potassium channel; LDHA, lactate dehydrogenase A; MAPK, mitogen-
activated protein kinases; MCT4, monocarboxylate transporter 4; PDH, pyruvate dehydrogenase; PDK1, pyruvate dehydrogenase kinase 1;
PI3K, phosphoinositide 3 kinase; SRC, proto-oncogene tyrosine-protein kinase; VHL, von Hippel–Lindau tumor suppressor; VEGF,
vascular endothelial growth factor.
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through which glycolytic enzymes (e.g., PKM2) can regulate
HIF-1a activity by stimulating its binding to HRE.67 During
hypoxic conditions, HIF-1a activates PDK1, which inhibits
PDH, avoiding the conversion of pyruvate in acetyl-CoA. In
these conditions, HIF-dependent activation of PDK1 pre-
vents ATP synthesis and also reduces ROS production pro-
tecting the cells from hypoxic stress damage.68
Hypoxia also induces changes in glutamine metabolism:
the HIF-1a-dependent amplification of the MYC oncogene
upregulates glutamine-metabolizing enzymes such as gluta-
minase; hypoxic cells with high MYC levels show increased
oxidative metabolism of glutamine.70 The HIF-1 signaling
pathway also leads to the upregulated expression ofMCT and
Na+/H+ exchanger.71 The extrusion of lactate and acid, with
pH reduction, is a typical feature of hypoxic cells. Hypoxia
contributes to the acid tumor microenvironment, which gives
the tumor a growth advantage, also upregulating carbonic
anhydrase-9 (CAIX), which exerts a feedback inhibition on
VHL protein, favoring the maintenance of high level of stable
HIF-1a.72
Acidification of pHe has been associated with nucleolar
sequestration of VHL, preventing it from targeting HIF-1a for
degradation. This suggests that the acidic tumor microenvi-
ronment may contribute to the metabolic shift, favoring the
maintenance of high HIF-1a levels. It is also evident that
acidification induced cellular mechanisms that can upregulate
the expression of transporters, such as NHE1 and NBCn1.
Moreover, hypoxia, through HIF-1a, promotes the expression
of several plasma membrane-located transporters, exchang-
ers, pumps, and ectoenzymes. Since altered pHi and pHe in
tumors may modulate cancer development through effects on
ion channels, we speculate that HIF-1a could affect also ion
channels, in particular pH-sensitive K+ channels. Indeed, an
important example is the family of two-pore K+ channels,
many members of which are highly pH sensitive in the rele-
vant range. Among these, the subfamily, including TASK-2,
TALK-1, and TALK-2, is activated by extracellular alkalin-
ization (pK½ for TASK-2 is 8.0) and hence would be expected
to be inhibited in the acidic tumor microenvironment. TASK-2
is additionally opened by intracellular alkalinization, and
yet, this cannot overcome the inhibitory effect of acidic pHe.
The regulation of TASK channels by tumor pHe is of par-
ticular interest because TASK channels, at least in some cell
types, are required for apoptosis, due to their role in apoptotic
volume decrease. This suggests that acidic tumor pHe may
contribute to death avoidance in cancer cells through inhi-
bition of two-pore K+ channels. Complicating the picture,
these channels are also implicated in cell cycle progression,
which would thus be counteracted by their acid-mediated
inhibition. In particular, TASK-3, which is inhibited by ex-
tracellular acidification, is overexpressed in ovarian cancer,
and TASK-3 blockers caused a significant reduction in cell
proliferation and an increase in apoptosis in SKOV-3 and
OVCAR-3 ovarian cancer cells.78
Ion Channels in Cancer: Focus on Sodium (Na+)
and Potassium (K+) Channels
Ion channels are integral membrane proteins that play a
key role in a variety of cell functions. Moreover, they have
been emerging as a novel class of membrane proteins ex-
pressed in several types of human cancers.79 In cells, K+
channels are involved in cell’s resting membrane poten-
tial,80 volume control,81 cell cycle progression,82 repolari-
zation,83 and cell proliferation.84 Here, we summarize the
current findings concerning the role of ion channels in cancer,
focusing on Na+ and K+ channels. Readers interested in a
complete description of Na+ and K+ channel members and
functions can refer to the following reviews.11–15
Voltage-activated sodium channels (VGSCs) drive Na+
influx in excitable cells and are involved in the action po-
tential generation and propagation.85 VGSC expression has
been found also in ‘‘nonexcitable’’ cells such as lympho-
cytes, osteoblasts, and endothelial cells.85 It was demon-
strated that VGSCs are expressed in breast86,87 prostate,88,89
lung,90,91 uterine cervix,92 and colorectal cancer93 and me-
sothelioma.94 In particular, it was demonstrated the VSGC
Nav1.5 is selectively upregulated in metastatic breast cancer
in vivo and in vitro and that VGSC activity is involved in
metastasis.86,93,95 Nav1.6 and/or Nav1.7 a-subunits have
been described in melanoma and lung and breast cancer.95
Nav1.9 expression is correlated with metastatic potential and
its activity increases cell migration in prostate cancer,88 and
invasiveness in nonsmall-cell lung cancers.96
Among potassium channels, voltage-gated potassium chan-
nel (Kv) has been reviewed in several publications.
97,98
Expression of ether-a go`-go` 1 (Eag1, also known as Kv10.1
or KCNH1) has been demonstrated in cell lines of different
histogenesis (neuroblastoma, breast, melanoma, colon, lung,
uterine cervix, and ovary)99 and it was shown that it is expressed
in human tumors, while being absent in the corresponding
normal tissues. Kv10.1 is expressed in esophageal squamous-
cell carcinoma compared with the corresponding normal tissue
and the protein correlates with depth of invasion.100
Kv11.1 (hERG1) is overexpressed in human primary
cancers such as endometrial,101 colorectal,102 esophageal,103
pancreatic,104 ovarian,105 and brain cancers,106 as well as
leukemias.107,108 It has been shown that the protein is highly
expressed in adenocarcinomas with respect to hyperplastic
lesions of endometrium101 and colon.102 In the latter, a cor-
relation between invasive phenotype and high Kv11.1 levels
of expression has been shown.102 Moreover, Kv11.1 posi-
tivity and GLUT-1 negativity represent an independent
negative prognostic factor in TNM-I and TNM-II colorectal
adenocarcinomas,25 identifying patients whose survival is
worse than stage TNM-III patients.109 Kv11.1 channel shows
a significant association with malignant progression toward
adenocarcinoma103; recently, the importance of Kv11.1 as a
biomarker has been demonstrated.110 Kv11.1 channels are
overexpressed also in gastric adenocarcinomas111 and in lung
cancer cell lines where they regulate cell proliferation.112
Kv1.3 is deregulated during prostate cancer progression, in
particular it is expressed in early stages, and downregulated
in high-grade cancers,113,114 and its expression is signifi-
cantly increased in higher stage breast cancer.115 Kv3.4 is
highly expressed in precancerous lesions and in oral squa-
mous cell carcinoma compared with normal oral mucosa.116
Ca2+-activated K+ channels (KCa’s) are also involved in
cancer. For example, functional KCa3.1 is expressed at high
levels on the plasma membrane of tumor cells of different
histogenesis: prostate adenocarcinoma,117 pancreatic118 and
breast cancer,119 gliomas,120 melanoma,121 and leukemias.122
KCa1.1 is amplified in late-stage prostate cancer.
123 Kir3.1 is
upregulated in pancreatic ductal adenocarcinoma (PDAC).124
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K2P family, in particular, K2P9.1 and K2P5.1 are expressed
in breast cancer125; K2P2.1 regulates cell proliferation of
prostate cancer.126
In the inner membrane, there are ion channels (in partic-
ular, K+ channels) that affect mitochondrial metabolic ac-
tivity, ROS synthesis, and other functions that are modified in
tumor cells. For these reasons, these channels are promising
targets for oncological therapies. In this case, ion channel
blockers are natural candidates for possible therapies. In fact,
a positive relationship was found between the mitoKATP
channel expression and the proliferation in glioma cells. In
contrast, in gastric cancer, impaired mitoKATP channel
opening is implicated in curcumin-induced apoptosis. In-
hibitors of the Kv1.3 channel (Psora-4, PAP-1, and clofazi-
mine) are able to cause apoptosis by directly targeting
mitoKv1.3. The mitoIKCa channel can be selectively in-
hibited by low concentrations of clotrimazole and TRAM-34.
This drug has been reported to synergistically increase the
sensitivity of melanoma cells to the death receptor ligand,
tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL), via its action on the mitoIKCa channel. The re-
duction of TASK-3 expression in WM35 melanoma cells
compromised mitochondrial function and cell survival. Re-
duced TASK-3 expression in WM35 and A2058 melanoma
cells decreased the viability, reduced the total DNA content,
changed the cell morphology, and promoted apoptosis.127
Relationships Between Na+, K+ Channels
and the Warburg Effect: A Unifying Landscape
Whereas the role of K+ and Na+ channels in metabolism of
cancer is still under study, more evidence exists for noncancer
cells (Table 1). For example, in epithelial cells, Na+ -gradients
are typically used to cotransport glucose across the cell mem-
brane.128 Also in cancer cells, glucose transport is facilitated by
sodium-dependent glucose transporters (SGLT). SGLT2 was
found functionally expressed in pancreatic and prostate ade-
nocarcinomas, and its inhibition decreased glucose uptake and
reduced tumor growth in a pancreatic cancer xenograft.129 In
astrocytes, lactate release is stimulated by K+ channels or de-
polarization,130 inwardly rectifying K+ channels 4.1 (Kir4.1)
involved in glutamate uptake,131 and the voltage-gated K+
channel Kv1.3 regulates GLUT-4 protein translocation at the
plasma membrane.132 As concerning cancer, immunohisto-
chemistry on surgical samples of nonmetastatic colorectal
cancer patients showed a correlation between the expression of
Kv11.1 and GLUT-1, as described above.
25,109
Dichloroacetate (DCA) has been tested as a potential
metabolic target therapy for cancer,133 and its effect has been
associated with changes in expression of Kv 4.1. DCA in-
hibits PDK, shifts the metabolism from glycolysis to glu-
cose oxidation, and suppresses tumor growth, in vitro and
in vivo.134 The DCA-mediated cell growth inhibition un-
dergoes increased Kv1.5 channel expression in breast cancer
cell lines.135
It has been demonstrated that for their ATP production,
gliomas depend disproportionately on glycolytic mecha-
nisms versus oxidative phosphorylation. This event leads to
increased proton-extruding proteins (Na+/H+ antiporter
NHE1 and H+-ATPase) and, finally, to decreased extracel-
lular pH. Spheroids obtained with glioma cells showed that
changes in external pH, as a consequence of Warburg effect,
are sensed by H+-sensitive K+ channels. These ion channels
translate these changes by modulating membrane voltage
(Vm) and glioma cell proliferation and tumorigenesis.
136
Current Knowledge About the Relationship
Between Hypoxia and Na+ and K+ Channels
In 1988, Lopez-Barneo gave the first description of hypoxia-
regulated ion channel, demonstrating that rabbit carotid body
glomus cells express an O2-sensitive K
+ channel.137 Since this
discovery, numerous studies have been carried out showing that
several ion channels, belonging to different families, are O2
sensitive and display changes in their activity with acute hyp-
oxia and their expression with prolonged hypoxic challenge.138
The first response of many cell types to hypoxia is characterized
by modifications in internal Ca2+ concentration ([Ca2+]i). Many
evidence exist about the involvement of different K+ channel
subtypes in this mechanism: the hypoxia-induced membrane
depolarization is mediated by the inhibition of the O2-sensitive
K+ channels, including Kv11.1, that activate voltage-gated
Ca2+ channels, causing an increase in [Ca2+]i.
138,139
Evidence of hypoxia-regulated ion channels exist also in
cancer. A study carried out on the human melanoma cell line
IGR1, reported that KCa channel activity is enhanced by
chronic hypoxia, and hypoxia mimetics, and that the HIF
sensory system is responsible for this process.140 Further-
more, cell proliferation is enhanced under hypoxic condition,
and the use of KCa channel blockers slows down cell growth.
141
The role of K+ channels as regulators of hypoxia-mediated
responses in cancer has been also investigated (Table 2). HIF-
1-mediated responses could be enhanced by members of the
ether-a`-go-go family. Their expression has been increasingly
linked to oncogenesis and tumor progression. The expression
of HIF-1a has been correlated to Kv10.1 level in breast cancer
tissues.142 These data are in agreement with those obtained in
cell lines, showing that Kv10.1 expression increases HIF-1a
levels and thus VEGF secretion, inducing tumor vasculari-
zation.73,97 Resistance to hypoxic condition could also be
enhanced by the overexpression of the K2P channel KCNK9
in human breast and small-cell lung tumors.143 Recently, also
Kv11.1 expression has been related to enhanced HIF(s)
transcriptional activation, sustaining angiogenesis and pro-
gression in colorectal cancer. The Kv11.1-dependent regu-
lation of HIF-1a, through the PI3K/Akt pathway, is triggered
in normoxia, especially after colorectal cancer cells have
experienced a hypoxic stage. Moreover, blocking Kv11.1
switches this pathway off in vitro and in vivo, by inhibiting
cell growth, angiogenesis, and metastatic spread.74
Recently, the role of another K2P channel, TASK-1 (or
KCNK3), was investigated in a subset of nonsmall-cell lung
cancers. TASK-1 expression influenced cell proliferation and
the channel current was inhibited in hypoxia. Moreover, Na+-
coupled nutrient transport across the cell membrane is
functionally coupled to the efflux of K+ via K+ channels, and
thus, TASK-1 may potentially influence Na+-coupled nutri-
ent transport.144 In Table 3, a list of oxygen-sensitive K+ and
Na+ channels in cancer is reported.
Antibodies as Tool to Target Macromolecular
Complexes Involved in Hypoxia Signaling
As reported above, it is well known the importance of ion
channels in a variety of cancer aspects. In particular, their role
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in controlling metabolic pathways and especially hypoxia is
possible thanks to their physical interactions with adhesion
molecules (such as integrins) and transporters, forming
proper central hubs controlling downstream signaling. In
particular, Kv11.1, which couples with b1 integrin, regulates
a novel signaling pathway that sustains angiogenesis and
progression in colorectal cancer. This pathway is triggered by
b1 integrin-mediated adhesion and leads to VEGF-A secre-
tion. Kv11.1 acts as a modulator recruiting and activating
PI3K and Akt. In turn, this increases HIF-dependent tran-
scription of VEGF-A and other tumor progression genes.74
Another example involving a Kv11.1-centered complex is
that of Kv11.1-CAIX in clear cell renal carcinoma, which is
also involved in sustaining hypoxic pathway (Lastraioli et al.;
submitted; under review). In this scenario, targeting such
macromolecular hubs with specific tools such as antibodies
will offer great opportunities for both diagnostics and therapy.
Antibodies have become common and essential research
instruments over the last 50 years, providing highly specific
and versatile tools for a wide array of experimental applica-
tions in many fields. Furthermore, monoclonal antibodies and,
more recently, recombinant antibodies have gained clinical
applications for diagnosis and therapy of different diseases,
including cancer.150,151 Specifically, a new class on antibodies
capable of binding two different antigens at the same time,
thus allowing the recognition of two independent targets that
might be crucial in the diagnostic and therapeutic setting is
that of bispecific antibodies, in the format of single-chain
variable fragment diabodies (scDb). scDbs conjugate bispe-
cificity with the characteristics of antibody fragments (low
molecular weight, high tissue penetration, and good clearance
times). Our group has already developed a bispecific scDb
antibody directed against the Kv11.1-b1 complex, selectively
expressed in cancers.152 Such antibody, once tested through
immunohistochemistry on both colorectal cancer and PDAC
tissue specimens, confirmed its specificity for the complex.
Such tools could be directed at ion channel complexes in-
volving cancer metabolism and/or hypoxia- related proteins
with the undeniable advantage of simultaneous dual targeting.
In this regard, it is known that Kv11.1 plays a significant role
in controlling several aspects of the tumor establishment and
progression, including pH regulation. As already noted, there
is a cross talk between Kv11.1 and b1, which complex to-
gether.152 Such interaction, in CRC, could involve NHE1,
which is involved in the control of intracellular pH.Moreover,
from the molecular point of view, Kv11.1-b1 and NHE1 form
a macromolecular complex that is highly expressed in CRC,
HCT116 cells.153
It has recently been shown that in clear renal-cell carci-
noma, Kv11.1 and CAIX are complexed together along with
b1 integrin, modulating several aspects of tumor progression
(Lastraioli et al.; submitted; under review). Overall, all these
results confirm the important role of b1-integrins in pH-
regulating mechanisms, demonstrating that Kv11.1 and NHE1
are involved in modulation of intracellular and extracellular
pH, the latter having a role of ‘‘mediator.’’ In this scenario, it
is worth validating recombinant bispecific or trispecific anti-
bodies as possible tools to be applied for diagnostic and
therapeutic purposes. Overall, the scDb–Kv11.1-b1 antibody
could represent a potential new treatment tool, as well as an
early molecular diagnostic marker, and thus could be an un-
deniable tool to target and decipher key actors of cancer
metabolism [Duranti et al., unpublished data].
Concluding Remarks and Future Perspectives
We have outlined here how metabolic changes in tumor
cells reciprocally interact with tumor hypoxia, and how this
involves major changes in ion channel expression and ion
transport across the plasma membrane. Mounting evidence
strongly indicates that these complex interconnections be-
tween ion channels, hypoxia, and the Warburg effect con-
tribute significantly to cancer development, by promoting, for
example, cell migration, invasion, and chemotherapy resis-
tance. In this context, we suggest that the specific roles of ion
channels may be exploited therapeutically. While the un-
derstanding of the roles and regulation of these ion channels
in cancer has increased greatly in recent years, understanding
the precise mechanism of ion channel-mediated hypoxic and
metabolic reprogramming in tumors represents an intriguing
Table 3. List of Oxygen-Sensitive K+ and Na+ Channels
Channel name Tumor type Hypoxia effect
KCa Channels Melanoma (IGR1 cells) Cell proliferation is enhanced
140,141
KCa1.1 Glioma (LN 2 cells) Acute hypoxia activates KCa1.1 channels residing in the mitochondrial
membrane, while no effect was observed on plasma membrane
KCa1.1 channels
145
Kv3.1, Kv3.4 Alveolar adenocarcinoma
(A549 cells), breast (MDA-
MB-231 cells), and colon
(HT-29 cells)
Cell density is incremented by HIF-1a, and expression of Kv3.1 and
Kv3.4 showed the same pattern with HIF-1a146
Kv10.1 Breast (tissues)
breast (MDA MB 231 cells)
Correlation of Kv10.1 expression with HIF-1a expression
142
Kv10.1 expression increases HIF-1a levels and thus VEGF secretion,
inducing tumor vascularization73
Kv11.1 Colorectal cancer (HCT116
cells)
Kv11.1 expression is related to enhanced HIF(s) transcriptional
activation, sustaining angiogenesis and progression74
TASK1 Subset of nonsmall-cell lung The channel current is inhibited in hypoxia144
TASK3 Lung (H146 cells) Maintains resting membrane potential147
VGSCs Various Increment of cell invasiveness148
a-ENaC Liver (HepG2 cells) Hypertonic stress (340/ 450 mosM) reversibly increased the Na+
conductance and proliferation149
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challenge. Future studies are warranted to address the precise
mechanism of the role of ion channels in Warburg effect
regulation. In turn, this could enable a move toward a pos-
sible clinical exploitation of the proposed evidence for the
role of such proteins in cancer metabolism remodeling and
tumor development.
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